Literature DB >> 21160821

New insights on cholangiocarcinoma.

Manuela Gatto1, Domenico Alvaro.   

Abstract

Cholangiocarcinoma (CCA) is a devastating cancer arising from the neoplastic transformation of the biliary epithelium. It is characterized by a progressive increase in incidence and prevalence. The only curative therapy is radical surgery or liver transplantation but, unfortunately, the majority of patients present with advanced stage disease, which is not amenable to surgical therapies. Recently, proposed serum and bile biomarkers could help in the screening and surveillance of categories at risk and in diagnosing CCA at an early stage. The molecular mechanisms triggering neoplastic transformation and growth of biliary epithelium are still undefined, but significant progress has been achieved in the last few years. This review deals with the most recent advances on epidemiology, biology, and clinical management of CCA.

Entities:  

Keywords:  Apoptosis; Cholangiocarcinoma; Cholangiocytes; Growth factors; Proliferation

Year:  2010        PMID: 21160821      PMCID: PMC2999173          DOI: 10.4251/wjgo.v2.i3.136

Source DB:  PubMed          Journal:  World J Gastrointest Oncol


  152 in total

1.  An increasing incidence of cholangiocarcinoma: why?

Authors:  Laurie Blendis; Zamir Halpern
Journal:  Gastroenterology       Date:  2004-09       Impact factor: 22.682

2.  Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation.

Authors:  K M Boberg; A Bergquist; S Mitchell; A Pares; F Rosina; U Broomé; R Chapman; O Fausa; T Egeland; G Rocca; E Schrumpf
Journal:  Scand J Gastroenterol       Date:  2002-10       Impact factor: 2.423

3.  Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.

Authors:  Tomislav Dragovich; Mark Huberman; Daniel D Von Hoff; Eric K Rowinsky; Paul Nadler; Debra Wood; Marta Hamilton; George Hage; Julie Wolf; Amita Patnaik
Journal:  Cancer Chemother Pharmacol       Date:  2006-12-06       Impact factor: 3.333

Review 4.  Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma.

Authors:  S Sell; H A Dunsford
Journal:  Am J Pathol       Date:  1989-06       Impact factor: 4.307

5.  c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma.

Authors:  S-I Aishima; K-I Taguchi; K Sugimachi; M Shimada; K Sugimachi; M Tsuneyoshi
Journal:  Histopathology       Date:  2002-03       Impact factor: 5.087

6.  Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer.

Authors:  Jeffrey A Meyerhardt; Andrew X Zhu; Keith Stuart; David P Ryan; Lawrence Blaszkowsky; Nicole Lehman; Craig C Earle; Matthew H Kulke; Pankaj Bhargava; Charles S Fuchs
Journal:  Dig Dis Sci       Date:  2007-06-29       Impact factor: 3.199

Review 7.  c-Met targeted therapy of cholangiocarcinoma.

Authors:  Matei-P Socoteanu; Frank Mott; Gianfranco Alpini; Arthur-E Frankel
Journal:  World J Gastroenterol       Date:  2008-05-21       Impact factor: 5.742

8.  Epirubicin, cisplatin, and protracted infusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma.

Authors:  Myung Ah Lee; In Sook Woo; Jin-Hyoung Kang; Young Seon Hong; Kyung Shik Lee
Journal:  J Cancer Res Clin Oncol       Date:  2004-02-28       Impact factor: 4.553

Review 9.  A review and update on cholangiocarcinoma.

Authors:  Matthew J Olnes; Rodrigo Erlich
Journal:  Oncology       Date:  2004       Impact factor: 2.935

10.  Gallstones and the risk of biliary tract cancer: a population-based study in China.

Authors:  A W Hsing; Y-T Gao; T-Q Han; A Rashid; L C Sakoda; B-S Wang; M-C Shen; B-H Zhang; S Niwa; J Chen; J F Fraumeni
Journal:  Br J Cancer       Date:  2007-11-13       Impact factor: 7.640

View more
  18 in total

Review 1.  Congenital hepatic fibrosis and autosomal recessive polycystic kidney disease.

Authors:  Arvind Srinath; Benjamin L Shneider
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-05       Impact factor: 2.839

Review 2.  [Pathological anatomical characteristics of Klatskin tumors. Classification, current molecular biological aspects, prognosis factors].

Authors:  J Munding; A Tannapfel
Journal:  Chirurg       Date:  2012-03       Impact factor: 0.955

3.  Oxaliplatin reverses the GLP-1R-mediated promotion of intrahepatic cholangiocarcinoma by altering FoxO1 signaling.

Authors:  Bendong Chen; Wenyan Zhou; Wenchao Zhao; Peng Yuan; Chaofeng Tang; Genwang Wang; Junzhi Leng; Jinlong Ma; Xiaowen Wang; Yongfeng Hui; Qi Wang
Journal:  Oncol Lett       Date:  2019-06-19       Impact factor: 2.967

4.  Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.

Authors:  F Bernuzzi; F Marabita; A Lleo; M Carbone; M Mirolo; M Marzioni; G Alpini; D Alvaro; K M Boberg; M Locati; G Torzilli; L Rimassa; F Piscaglia; X-S He; C L Bowlus; G-X Yang; M E Gershwin; P Invernizzi
Journal:  Clin Exp Immunol       Date:  2016-05-17       Impact factor: 4.330

Review 5.  The cholangiocyte primary cilium in health and disease.

Authors:  Adrian P Mansini; Estanislao Peixoto; Kristen M Thelen; Cesar Gaspari; Sujeong Jin; Sergio A Gradilone
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-06-15       Impact factor: 5.187

Review 6.  The significance of genetics for cholangiocarcinoma development.

Authors:  Luca Maroni; Irene Pierantonelli; Jesus M Banales; Antonio Benedetti; Marco Marzioni
Journal:  Ann Transl Med       Date:  2013-10

7.  A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma.

Authors:  Amy L Collins; Sylwia Wojcik; James Liu; Wendy L Frankel; Hansjuerg Alder; Lianbo Yu; Thomas D Schmittgen; Carlo M Croce; Mark Bloomston
Journal:  Ann Surg Oncol       Date:  2013-09-18       Impact factor: 5.344

8.  Surgical management trends for cholangiocarcinoma in the USA 1998-2009.

Authors:  Jamie E Anderson; Alan W Hemming; David C Chang; Mark A Talamini; Kristin L Mekeel
Journal:  J Gastrointest Surg       Date:  2012-07-31       Impact factor: 3.452

9.  Mandibular metastasis of cholangiocarcinoma: A case report.

Authors:  Tae Min You; Kee-Deog Kim; Ho-Gul Jeong; Wonse Park
Journal:  Imaging Sci Dent       Date:  2015-12-17

10.  Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil.

Authors:  Chariya Hahnvajanawong; Jariya Chaiyagool; Wunchana Seubwai; Vajarabhongsa Bhudhisawasdi; Nisana Namwat; Narong Khuntikeo; Banchob Sripa; Ake Pugkhem; Wichittra Tassaneeyakul
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.